Lymphocyte‐predominant and classical Hodgkin's lymphoma – comparison of outcomes
- 6 June 2005
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 75 (s66), 106-110
- https://doi.org/10.1111/j.1600-0609.2005.00462.x
Abstract
Lymphocyte predominant Hodgkin's lymphoma (LPHL) differs in histological and clinical presentation from classical Hodgkin's lymphoma (cHL). Treatment of LPHL patients using standard Hodgkin's lymphoma (HL) protocols leads to complete remission (CR) in more than 95% of patients. However, differences in terms of relapse rates, survival and freedom from treatment failure (FFTF) between LPHL and cHL patients were suggested by a recent intergroup analysis. To obtain a more comprehensive picture, we reviewed all LPHL-cases registered in the GHSG database and compared patient characteristics and treatment outcome with cHL patients. We retrospectively analyzed 8298 HL patients treated within the GHSG trials (HD4-HD12): 394 LPHL patients and 7904 cHL patients. From 394 LPHL patients 63% were in early stage, 16% in intermediate and 21% in advanced stage of disease. Of the 7904 cHL patients analyzed, 22% were in early, 39% in intermediate and 39% in advanced stages. About 9% of LPHL patients had B symptoms compared to 40% in cHL patients. About 91% LPHL vs. 86% cHL patients in early stages, 86% vs. 83% in intermediate and 79% vs. 75% in advanced stages reached CR/CRu. Additional analysis for LPHL IA patients showed 98% CR/CRu after extended field, 100% after involved field (IF) and 98% CR/CRu after combined modality treatment. About 0.3% LPHL patients developed progressive disease (PD) compared to 3.7% cHL patients. The relapse rate of LPHL patients was very similar to cHL (8.1% vs. 7.9%). There were 2.5% secondary malignancies in LPHL and 3.7% in cHL patients. About 4.3% LPHL patients and 8.8% cHL patients died. The FFTF rates for LPHL and cHL patients at a median observation of 41 or 48 months were 92% and 84%, respectively. The OS for LPHL and cHL patients was 96% and 92%, respectively. The cHL patients present more frequently with advanced stages and B symptoms compared to LPHL patients. There was no difference in treatment outcome in terms of CR/CRu, PD and mortality between LPHL and HL. Surprisingly, there were also no differences in patients with relapse.Keywords
This publication has 12 references indexed in Scilit:
- Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiationBlood, 2004
- Results of Little or No Treatment for Lymphocyte-Predominant Hodgkin Disease in Children and AdolescentsJournal of Pediatric Hematology/Oncology, 2003
- Lymphocyte-Predominant Hodgkin’s Lymphoma in Children: Therapeutic Abstention After Initial Lymph Node Resection—A Study of the French Society of Pediatric OncologyJournal of Clinical Oncology, 2003
- Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trialBlood, 2003
- Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study GroupBlood, 2003
- Radiotherapy Alone for Lymphocyte-Predominant Hodgkin??s DiseaseThe Cancer Journal, 2002
- European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte‐predominant Hodgkin diseaseCancer, 2002
- Clinical Presentation, Course, and Prognostic Factors in Lymphocyte-Predominant Hodgkin's Disease and Lymphocyte-Rich Classical Hodgkin's Disease: Report From the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's DiseaseJournal of Clinical Oncology, 1999
- Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.Journal of Clinical Oncology, 1997
- Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experienceAnnals of Oncology, 1991